IDEAYA Biosciences Files Administrative 8-K; No New Material Info

TL;DR

**IDEAYA Biosciences filed a routine 8-K, no big news for traders.**

AI Summary

IDEAYA Biosciences, Inc. filed an 8-K on January 23, 2024, reporting an 'Other Events' item from January 22, 2024. This filing primarily serves to update administrative information, confirming its status as a Delaware corporation with its principal executive offices at 7000 Shoreline Court, Suite 350, South San Francisco, California. For investors, this filing is largely administrative and does not contain new material financial or operational news that would directly impact the stock price, but it confirms the company's ongoing compliance with SEC reporting requirements.

Why It Matters

This filing is largely administrative, confirming basic company details and SEC compliance, which is important for maintaining transparency but doesn't introduce new financial or operational data.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative and does not contain any information that would introduce new risks or change the company's risk profile.

Analyst Insight

A smart investor would note this filing as routine compliance and not indicative of any immediate need to buy, sell, or hold based on its content. It's a confirmation of existing public information.

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for IDEAYA Biosciences, Inc.
• 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (company) — principal executive offices of IDEAYA Biosciences, Inc.
• IDYA (company) — trading symbol for IDEAYA Biosciences, Inc.
• The Nasdaq Global Select Market (company) — exchange where IDEAYA Biosciences, Inc. common stock is registered

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
• $350.0 million — aving aggregate gross proceeds of up to $350.0 million through Jefferies as sales agent, under
• $126.9 million — for aggregate estimated net proceeds of $126.9 million at a weighted average sales price of ap
• $41.50 — ed average sales price of approximately $41.50 per share under the at-the-market offer
• $220.5 million — . As of January 23, 2024, approximately $220.5 million of common stock remained available to b

Filing Documents

• idya-20240122.htm (8-K) — 38KB
• 0000950170-24-006249.txt ( ) — 156KB
• idya-20240122.xsd (EX-101.SCH) — 30KB
• idya-20240122_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. As previously disclosed, IDEAYA Biosciences, Inc. (the “Company”) entered into an Open Market Sales Agreement, dated January 19, 2024 (the “January 2024 Sales Agreement”), with Jefferies LLC (“Jefferies”) relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (“common stock”), having aggregate gross proceeds of up to $350.0 million through Jefferies as sales agent, under an automatic shelf registration statement on Form S-3ASR (File No. 333- 272936), filed with the Securities and Exchange Commission on June 26, 2023. On January 22, 2024, the Company sold an aggregate of 3,119,866 shares of common stock for aggregate estimated net proceeds of $126.9 million at a weighted average sales price of approximately $41.50 per share under the at-the-market offering pursuant to the January 2024 Sales Agreement. As of January 23, 2024, approximately $220.5 million of common stock remained available to be sold under the at-the-market facility associated with the January 2024 Sales Agreement.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: January 23, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR